Title

Terconazole Vaginal Suppository vs Fluconazole for the Treatment of Severe Vulvovaginal Candidiasis
A Randomized, Parallel-group Study of Terconazole Vaginal Suppository vs Fluconazole for the Treatment of Severe
  • Phase

    Phase 4
  • Study Type

    Interventional
  • Study Participants

    140
The objectives of this study were to demonstrate comparable safety and efficacy of Terconazole Vaginal Suppositories, 80 mg and fluconazole in the treatment of subjects with severe vulvovaginal candidiasis.
This study were to demonstrate comparable safety and efficacy of Terconazole Vaginal Suppository 80 mg inserted intravaginally once daily before bedtime for 6 consecutive days and oral fluconazole 150mg at day 1 and day 4 in the treatment of subjects with severe vulvovaginal candidiasis.
Study Started
Aug 31
2013
Primary Completion
Jun 30
2014
Study Completion
Jun 30
2014
Results Posted
Oct 23
2020
Last Update
Oct 23
2020

Drug Terconazole Vaginal Suppository

Terconazole Vaginal Suppository inserted intravaginally once daily before bedtime for 6 consecutive days

  • Other names: Tekangzuo Yindao Shuan

Drug Fluconazole

orally Fluconazole 150 mg (Pfizer Pharmaceuticals) at day 1 and day 4.

  • Other names: Diflucan

Terconazole Vaginal Suppository Experimental

Terconazole Vaginal Suppository inserted intravaginally once daily before bedtime for 6 consecutive days

Fluconazole Active Comparator

orally Fluconazole 150 mg (Pfizer Pharmaceuticals) at day 1 and day 4.

Criteria

Inclusion Criteria:

Vulvovaginal candidiasis infection is diagnosed, the symptoms evaluated using a numerical rating system based on severity (absent=0; mild=1; moderate=2; severe=3) with a minimum VVC Composite Signs/Symptoms score of 7
Subject completes the informed consent process
Subject agrees to take study medication when scheduled
Subject complies with all clinical trial instructions. Commits to all follow-up visits
Subject agrees to abstain from sexual intercourse from the time of randomization through the first seven days immediately following treatment

Exclusion Criteria:

had any other sexually transmitted disease or gynaecological abnormality requiring treatment
had a disease known to predispose to candidiasis such as diabetes mellitus, or were receiving antibiotics or corticosteriods
had used antifungal medication in the week before entry; or
were expected to menstruate within seven days of the start of treatment
infected more than one candida species

Summary

Terconazole Vaginal Suppository

Fluconazole

All Events

Event Type Organ System Event Term

Mycological Cure 1

Based on candida culture

Terconazole Vaginal Suppository

Fluconazole

Mycological Cure 2

Based on Candida culture

Terconazole Vaginal Suppository

Fluconazole

Total

140
Participants

Age, Categorical

Sex: Female, Male

Overall Study

Terconazole Vaginal Suppository

Fluconazole